Oral Labetalol Half-Life and Pharmacodynamics
The plasma elimination half-life of oral labetalol is approximately 6 to 8 hours, with complete gastrointestinal absorption but only 25% absolute bioavailability due to extensive first-pass hepatic metabolism. 1
Pharmacokinetic Profile
Absorption and Bioavailability
- Oral labetalol is completely absorbed from the gastrointestinal tract, with peak plasma concentrations occurring 1 to 2 hours after administration 1
- Absolute bioavailability is only 25% when compared to IV administration, secondary to extensive first-pass hepatic metabolism 1
- Food administration increases the absolute bioavailability of labetalol 1
- Despite significant first-pass metabolism, there is a linear relationship between oral doses of 100 to 3,000 mg and peak plasma levels 1
Distribution and Elimination
- Plasma half-life ranges from 6 to 8 hours following oral administration 1
- Steady-state plasma levels are reached by approximately the third day of repetitive dosing 1
- Labetalol is approximately 50% protein bound 1
- The drug undergoes metabolism primarily through conjugation to glucuronide metabolites, with approximately 55% to 60% of a dose appearing in urine as conjugates or unchanged drug within the first 24 hours 1
Special Population Considerations
- In patients with hepatic impairment, the elimination half-life is not altered, but relative bioavailability is increased due to decreased first-pass metabolism 1
- In patients with renal dysfunction, the elimination half-life remains unchanged 1
- Elderly patients demonstrate reduced elimination of labetalol and generally require lower maintenance dosages than younger patients 1
- Neither hemodialysis nor peritoneal dialysis removes significant amounts of labetalol from circulation (<1%) 1
Pharmacodynamic Profile
Onset and Peak Effects
- Peak antihypertensive effects occur within 2 to 4 hours after a single oral dose 1
- Symptomatic postural hypotension is most likely to occur 2 to 4 hours after a dose, particularly following large initial doses or significant dose changes 1
Duration of Action
- The duration of effect is dose-dependent: lasting at least 8 hours following 100 mg doses and more than 12 hours following 300 mg doses 1
- Maximum steady-state blood pressure response occurs within 24 to 72 hours with twice-daily dosing 1
Beta-Blocking Effects
- Approximately 70% of the maximum beta-blocking effect persists for 5 hours after a single 400 mg oral dose, with approximately 40% remaining at 8 hours 1
- There is a linear correlation between the reduction in exercise-induced tachycardia at 2 hours and the logarithm of plasma concentration 1
Hemodynamic Effects
- The antihypertensive effect has a linear correlation with the logarithm of labetalol plasma concentration 1
- Due to alpha-1 receptor blocking activity, blood pressure is lowered more in the standing than supine position 1
- Unlike conventional beta-blockers, labetalol produces decreased peripheral vascular resistance with little alteration in heart rate or cardiac output when given acutely 2
Clinical Implications
Dosing Considerations
- The wide interindividual variability in plasma concentrations (bioavailability ranging from 11% to 86% in some studies) necessitates individualized dose titration 3
- Labetalol crosses the placental barrier in humans, though only negligible amounts cross the blood-brain barrier 1
Withdrawal Precautions
- Abrupt discontinuation in patients with coronary artery disease has been associated with exacerbation of angina, myocardial infarction, and ventricular dysrhythmias 1
- Even in patients without coronary disease, abrupt withdrawal can cause transient symptoms including tremulousness, sweating, palpitation, headache, and malaise 1